drugset / Trial / NCT03505996
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, single-arm phase II study to evaluate the efficacy and safety of CS1001 monotherapy for relapsed/refractory classical Hodgkin Lymphoma (rr-cHL)
Timeline
- Start
- 2018-05-22
- Primary completion
- 2020-02-19
- Completion
- 2021-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sugemalimab | Monoclonal antibody | 1200 mg | Intravenous |